{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:22:29Z","timestamp":1791404549609,"version":"4.3.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,7,7]],"date-time":"2009-07-07T00:00:00Z","timestamp":1246924800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s00277-009-0777-8","type":"journal-article","created":{"date-parts":[[2009,7,6]],"date-time":"2009-07-06T06:42:20Z","timestamp":1246862540000},"page":"25-33","source":"Crossref","is-referenced-by-count":35,"title":["Serum cytokines in follicular lymphoma. Correlation of TGF-\u03b2 and VEGF with survival"],"prefix":"10.1007","volume":"89","author":[{"given":"Sana Intidhar","family":"Labidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"M\u00e9n\u00e9trier-Caux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Chabaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Chassagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sebban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Gargi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Biron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,7,7]]},"reference":[{"key":"777_CR1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","volume":"16","author":"JO Armitage","year":"1998","unstructured":"Armitage JO, Weinsenburger DD (1998) New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 16:2780\u20132795","journal-title":"J Clin Oncol"},{"key":"777_CR2","first-page":"75","volume":"20","author":"SJ Horning","year":"1993","unstructured":"Horning SJ (1993) Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75\u201388","journal-title":"Semin Oncol"},{"key":"777_CR3","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","volume":"24","author":"Q Liu","year":"2006","unstructured":"Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M et al (2006) Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25\u00a0years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24:1582\u20131589","journal-title":"J Clin Oncol"},{"key":"777_CR4","doi-asserted-by":"crossref","unstructured":"Coiffier B, Brice P, Delarue R, Haioun C, Souleau B, Mounier N et al (2007) Effect of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma. Blood (ASH annual meeting abstracts) 110, Abstract 386","DOI":"10.1182\/blood.V110.11.386.386"},{"key":"777_CR5","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258\u20131265","journal-title":"Blood"},{"key":"777_CR6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/asheducation-2007.1.216","volume":"2007","author":"GA Salles","year":"2007","unstructured":"Salles GA (2007) Clinical features, prognosis and treatment of follicular lymphoma. Hematology 2007:216\u2013225","journal-title":"Hematology"},{"key":"777_CR7","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1200\/JCO.2005.26.856","volume":"23","author":"D Jong De","year":"2005","unstructured":"De Jong D (2005) Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 23:6358\u20136363","journal-title":"J Clin Oncol"},{"key":"777_CR8","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC et al (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159\u20132169","journal-title":"N Engl J Med"},{"key":"777_CR9","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","volume":"108","author":"J Carreras","year":"2006","unstructured":"Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G et al (2006) High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108:2957\u20132964","journal-title":"Blood"},{"key":"777_CR10","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2006.06.4642","volume":"24","author":"AM Lee","year":"2006","unstructured":"Lee AM, Clear AJ, Calaminici M, Davies AJ, Jordan S, MacDougall F et al (2006) Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 24:5052\u20135059","journal-title":"J Clin Oncol"},{"key":"777_CR11","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","volume":"106","author":"P Farinha","year":"2005","unstructured":"Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K et al (2005) Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 106:2169\u20132174","journal-title":"Blood"},{"key":"777_CR12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2007.12.8298","volume":"26","author":"D Canioni","year":"2008","unstructured":"Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F et al (2008) High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 26:440\u2013446","journal-title":"J Clin Oncol"},{"key":"777_CR13","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2006.08.1331","volume":"25","author":"RO Casanovas","year":"2007","unstructured":"Casanovas RO, Mounier N, Brice P, Divine M, Morschhauser F, Gabarre J et al (2007) Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25:1732\u20131740","journal-title":"J Clin Oncol"},{"key":"777_CR14","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.V82.7.2169.2169","volume":"82","author":"JY Blay","year":"1993","unstructured":"Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T et al (1993) Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 82:2169\u20132174","journal-title":"Blood"},{"key":"777_CR15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00277-005-1020-x","volume":"84","author":"LM Pedersen","year":"2005","unstructured":"Pedersen LM, Klausen TW, Davidsen UH, Johnsen HE (2005) Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol 84:510\u2013516","journal-title":"Ann Hematol"},{"key":"777_CR16","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V96.12.3712","volume":"96","author":"P Salven","year":"2000","unstructured":"Salven P, Orpana A, Teerenhovi L, Joensuu H (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 96:3712\u20133718","journal-title":"Blood"},{"key":"777_CR17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/10428199809057568","volume":"30","author":"L Fayad","year":"1998","unstructured":"Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kuzrock R (1998) High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma 30:563\u2013571","journal-title":"Leuk Lymphoma"},{"key":"777_CR18","unstructured":"Ansell SM, Novak AJ, Ziesmer S, LaPlant B, Cerhan JR, Yang ZZ et al (1997) Serum cytokine levels predict time to progression after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 110, abstract 3410"},{"key":"777_CR19","first-page":"1860","volume":"31","author":"PP Carbone","year":"1971","unstructured":"Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the committee on Hodgkin's disease staging classification. Cancer Res 31:1860\u20131861","journal-title":"Cancer Res"},{"key":"777_CR20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0022-1759(00)00238-6","volume":"243","author":"DA Vignali","year":"2000","unstructured":"Vignali DA (2000) Multiplexed particle-based flow cytometric assays. J Immunol Methods 243:243\u2013255","journal-title":"J Immunol Methods"},{"key":"777_CR21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"777_CR22","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling survival data: extending the Cox model","author":"T Therneau","year":"2000","unstructured":"Therneau T, Grambsch P (2000) Modeling survival data: extending the Cox model. Springer, New York"},{"key":"777_CR23","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1182\/blood-2006-11-058040","volume":"109","author":"JR Cerhan","year":"2007","unstructured":"Cerhan JR, Wang S, Maurer MJ, Ansell SM, Geyer SM, Cozen W et al (2007) Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 109:5439\u20135446","journal-title":"Blood"},{"key":"777_CR24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s002620050483","volume":"46","author":"VP Khatri","year":"1998","unstructured":"Khatri VP, Caligiuri MA (1998) A review of the association between interleukin-10 and human B-cell malignancies. Cancer Immunol Immunother 46:239\u2013244","journal-title":"Cancer Immunol Immunother"},{"key":"777_CR25","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1172\/JCI116977","volume":"93","author":"Y Levy","year":"1994","unstructured":"Levy Y, Brouet JC (1994) Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 93:424\u2013428","journal-title":"J Clin Invest"},{"key":"777_CR26","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1182\/blood-2003-06-1850","volume":"103","author":"E Lech-Maranda","year":"2004","unstructured":"Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D et al (2004) Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103:3529\u20133534","journal-title":"Blood"},{"key":"777_CR27","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1182\/blood.V85.12.3423.bloodjournal85123423","volume":"85","author":"R Masood","year":"1995","unstructured":"Masood R, Zhang Y, Bond MW, Scadden DT, Moudgil T, Law RE et al (1995) Interleukin-10 is an autocrine growth factor for acquired immunodeficiency syndrome-related B-cell lymphoma. Blood 85:3423\u20133430","journal-title":"Blood"},{"key":"777_CR28","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S1286-4579(99)00254-3","volume":"1","author":"DA Lebman","year":"1999","unstructured":"Lebman DA, Edmiston JS (1999) The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. Microbes Infect 1:1297\u20131304","journal-title":"Microbes Infect"},{"key":"777_CR29","doi-asserted-by":"crossref","first-page":"F19","DOI":"10.1084\/jem.194.4.F19","volume":"194","author":"P Golstein","year":"2001","unstructured":"Golstein P, Wyllie AH (2001) T cell death and transforming growth factor beta1. J Exp Med 194:F19\u2013F22","journal-title":"J Exp Med"},{"key":"777_CR30","first-page":"BR227","volume":"12","author":"D Tvrdik","year":"2006","unstructured":"Tvrdik D, Dundr P, Povysil G, Pytlik R, Plankova M (2006) Up-regulation of p21WAF1 expression is mediated by Sp1\/Sp3 transcription factors in TGFbeta1-arrested malignant B cells. Med Sci Monit 12:BR227\u2013BR234","journal-title":"Med Sci Monit"},{"key":"777_CR31","first-page":"BR447","volume":"10","author":"D Tvrdik","year":"2004","unstructured":"Tvrdik D (2004) The effect of TGFbeta1 on the expression and phosphorylation of key cell-cycle regulators in malignant B cells. Med Sci Monit 10:BR447\u2013BR454","journal-title":"Med Sci Monit"},{"key":"777_CR32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood.V99.1.282","volume":"99","author":"H Husson","year":"2002","unstructured":"Husson H, Carideo EG, Neuberg D, Schultze J, Munoz A, Marks PW et al (2002) Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. Blood 99:282\u2013289","journal-title":"Blood"},{"key":"777_CR33","doi-asserted-by":"crossref","unstructured":"Huse K, Bakkebo M, Oksvold M, Smeland EB, Myklebust JH (2007) B cell lymphomas escape bone morphogenetic protein (BMP) induced growth inhibition: downregulation of BMP receptors and upregulation of inhibitory Smads. Blood (American Society of Hematology) 110, Abstract 2605","DOI":"10.1182\/blood.V110.11.2605.2605"},{"key":"777_CR34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1080\/10428190701200059","volume":"48","author":"K Ganjoo","year":"2007","unstructured":"Ganjoo K (2007) Antiangiogenesis: a new approach to the treatment of lymphoma. Leuk Lymphoma 48:454\u2013455","journal-title":"Leuk Lymphoma"},{"key":"777_CR35","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/10428190601083241","volume":"48","author":"JM Jorgensen","year":"2007","unstructured":"Jorgensen JM, Sorensen FB, Bendix K, Nielsen JL, Olsen ML, Funder AM et al (2007) Angiogenesis in Non-Hodgkin Lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 48:584\u2013595","journal-title":"Leuk Lymphoma"},{"key":"777_CR36","unstructured":"Stopeck AT, Bellamy W, Unger J, Rimsza L, Lannone M, Fisher RI et al (2005) Phase II trial of single agent bevacizumab (Avastin) in patients with relapsed, aggressive non-Hodgkin's lymphoma (NHL): Southwest Oncology Group Study S0108. J Clin Oncol (ASCO Annual Meeting), Abstract 6592"},{"key":"777_CR37","unstructured":"Sorafenib in treating patients with recurrent diffuse large B-cell non-Hodgkin\u2019s lymphoma (2008) http:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT00131937"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-009-0777-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-009-0777-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-009-0777-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T07:52:00Z","timestamp":1589961120000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-009-0777-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,7]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1007\/s00277-009-0777-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,7]]}}}